Orixha

WHY THIS PROJECT ?

The Orixha project was born from the shared ambition of its co-founders in Quebec and France: making Total Liquid Ventilation (TLV) a clinical reality in critical care. The company was founded in 2018 by researchers and clinicians with a single goal—to bring the clinical benefits of liquid ventilation to critically ill patients. Their existential question is whether, by offering a safe liquid ventilation platform, they can save millions of patients.

THE MISSION

Orixha's mission, as stated in its Corporate charters,  is to “Save Critical Care Patients’ Lives thanks to our Proprietary Liquid Ventilation Technology”. Orixha is in the process of clinically validating the first Total Liquid Ventilation (TLV) technology to enable intensivists and critical care professionals to improve patient outcomes. Their solutions, based on their proprietary clinical platform LuncoLive, promise to address major unmet medical needs in intensive care, such as, post-cardiac arrest syndrome (with Vent2Cool) and respiratory distress (with Vent2Breathe). 

A DISRUPTIVE INNOVATION

The disruptive idea primarily lies in the development and application of their proprietary Total Liquid Ventilation (TLV) technology, called LuncoLive. This technology represents a fundamentally different approach to traditional mechanical ventilation by using a breathable liquid instead of gas.

More specifically, this disruptive innovation is embodied in two life-saving medical solutions:

Vent2Cool: Hypothermic total liquid ventilation, by Vent2Cool, allows for ultra-rapid cooling to 33°C protective hypothermia of resuscitated cardiac arrest patients in just 30 minutes. It is presented as a significant improvement over existing cooling methods which takes several hours to achieve protective therapeutic hypothermia, with the goal of greatly enhancing survival rates and neurological outcomes.

Vent2Breathe: Currently under preclinical development, this solution is designed for respiratory support in patients suffering from Acute Respiratory Distress Syndrome (ARDS). Normothermic TLV by Vent2Breathe offers a novel method for oxygenation and carbon dioxide removal using a breathable liquid, which could be particularly beneficial for patients with severe lung inflammation. 

POSITIVE IMPACT ON THE SOCIETY

Orixha project has a significant positive societal impact by addressing major unmet medical needs in intensive care and offering new life-saving therapeutic options. The LuncoLive-based medical devices have experimentally demonstrated numerous advantages of lung-conservative liquid ventilation in several critical care settings. Orixha aims to significantly improve survival rates and quality of life for critically ill patients. Their project aligns with the United Nations' Sustainable Development Goals (SDGs), particularly:

SDG 3: Good Health and Well-being – By developing innovative liquid ventilation technology, Orixha contributes to improving patient survival rates and quality of life in critical care settings.

SDG 9: Industry, Innovation, and Infrastructure – Their groundbreaking LuncoLive platform represents a major technological advancement in medical ventilation, pushing the boundaries of healthcare innovation.

SDG 17: Partnerships for the Goals – Orixha collaborates with international clinical and scientific experts, fostering global partnerships to advance medical research and innovation.

LEVERAGING THE 3DEXPERIENCE PLATFORM

Orixha anticipates that the 3DEXPERIENCE platform will significantly enhance collaboration among employees and partners already working together across five countries. They plan to use tools such as SolidWorks for product, tooling, and fixture design, and ENOVIA to structure their supply chain management and quality management systems. The platform could also help them evaluate all modeling and simulation possibilities to maximize the efficiency of their technology.

COLLABORATIVE & COLLECTIVE INTELLIGENCE

Orixha consists of a multidisciplinary and transatlantic team combining expertise in engineering, pathophysiology, and pharmacology. Their leadership team includes 5 members within a group of 8 full-time employees. They are supported by key clinical advisors such as Prof. Cariou, Lamhaut, Ricard and Vicaut in France, Prof. Taccone in Belgium (all members of Orixha’s scientific committee) and scientific advisors in Canada who are experts in liquid ventilation, all aligned with their mission. The 3DEXPERIENCE platform itself is intended to enhance collaborative work within their international network.